デフォルト表紙
市場調査レポート
商品コード
1440045

鎮痛剤 - 世界市場の考察、競合情勢、市場予測(2030年)

Analgesics - Market Insights, Competitive Landscape, and Market Forecast - 2030

出版日: 受注後更新 | 発行: DelveInsight | ページ情報: 英文 150 Pages | 納期: 2~10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
鎮痛剤 - 世界市場の考察、競合情勢、市場予測(2030年)
出版日: 受注後更新
発行: DelveInsight
ページ情報: 英文 150 Pages
納期: 2~10営業日
ご注意事項 :
本レポートの納品は、最新情報反映のため受注時に適宜更新しお届けいたします。
更新情報の反映作業にあたり納期もレポート毎に異なりますので、ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の鎮痛剤の市場規模は、2023年に305億9,900万米ドル、2030年までに453億8,900万米ドルに達し、2024年~2030年の予測期間にCAGRで6.84%の成長が見込まれます。整形外科疾患、がん、その他の慢性疾患の有病率の増加、軽度から中等度の痛みの治療に用いる鎮痛剤への需要の増加、老年人口の負担の増加、鎮痛剤の安全性、有効性、使いやすさの改善に対する関心の高まりにより、市場は活況を呈する見込みであり、これらがさらに予測期間(2024年~2030年)の市場の大きな収益成長につながると予測されます。

鎮痛剤の市場力学

世界保健機関(WHO)(2022)によると、2020年に世界で約226万件の乳がん、221万件の肺がん、193万件の大腸がん、141万件の前立腺がん、109万件の胃がんが報告されています。

変形性関節症、関節リウマチなどの整形外科疾患の有病率の上昇も、鎮痛剤市場の重要な促進要因です。世界保健機関(WHO)(2022)によると、筋骨格系疾患は障害の主因であり、世界中で約17億1,000万人が骨粗鬆症、変形性関節症、関節リウマチなどの筋骨格系疾患に苦しんでいます。WHO(2022)によると、2019年に世界中で約5億2,800万人が変形性関節症を患っていました。同じ資料によると、2019年に世界中で1,800万人が関節リウマチを患っていました。

変形性関節症は、しばしば退行性関節炎または摩耗性関節炎と呼ばれ、関節に影響を及ぼし、結果として骨の表面の滑らかな軟骨の摩耗を引き起こします。患者は大きな痛み、浮腫、関節の炎症に直面し、自由に動くことが制限されます。そのため、痛みを治療するために鎮痛剤が使用されます。

さらに、歯痛、頭痛、激しい運動による痛み、生理痛など、軽度から中等度の痛みの治療に用いる鎮痛剤への需要の向上も、鎮痛剤市場の成長促進要因です。

しかし、オピオイドの乱用に対する懸念の高まりと厳しい規制政策が、鎮痛剤市場の成長抑制要因として作用する可能性があります。

COVID-19パンデミックは鎮痛剤市場に若干の影響を与えています。パンデミックの初期段階では、厳格なロックダウン規制が敷かれ、製造と供給が中断されたため、鎮痛剤の売上は落ち込みました。また、厳格なロックダウン規制により、多くの選択的手術や診断が延期され、鎮痛剤の需要に影響を与えました。しかし、アセトアミノフェン(パラセタモール)などの鎮痛剤があり、COVID-19患者は発熱や痛みなどの症状を和らげるために服用していました。さらに、ロックダウン規制の緩和、リソースとサプライチェーンの好転、大衆へのワクチン投与、慢性疼痛と炎症関連疾患の手術および診断の増加により、鎮痛剤の需要は拡大すると予測され、2022年~2028年の予測期間にも同様の需要が見込まれます。

鎮痛剤市場のセグメント分析

鎮痛剤市場の製品タイプセグメントでは、予測期間(2024年~2030年)に非オピオイドカテゴリが市場全体で収益の大幅な成長を記録すると予測されます。非オピオイド鎮痛剤は、リウマチ性疾患による筋骨格系の痛みなどのさまざまな痛みや炎症疾患に適しており、効果的です。非オピオイド鎮痛剤は、オピオイド鎮痛剤に比べて副作用が少ないです。

一般的に使用される鎮痛剤は、アセトアミノフェン(パラセタモール)、デュロキセチンやアミトリプチリンなどの抗うつ薬、アスピリンなどの非ステロイド性抗炎症薬(NSAIDS)、リドカインやカプサイシンなどの外用薬などです。

アセトアミノフェンは、頭痛、生理痛、腰痛などの軽度から中等度の痛みに適応があります。アセトアミノフェンは、痛みや発熱、特にウイルス感染に対する第一選択薬とされています。

非ステロイド性抗炎症薬(NSAIDs)は、痛みを軽減し、解熱作用があり、血栓を予防し、体内で痛みや炎症を引き起こすプロスタグランジンなどの酵素を阻害することで炎症を抑えることができます。

当レポートでは、世界の鎮痛剤市場について調査分析し、市場規模と予測、促進要因と課題、企業と製品のプロファイルなどを提供しています。

目次

第1章 鎮痛剤市場レポートのイントロダクション

第2章 鎮痛剤市場のエグゼクティブサマリー

  • 調査範囲
  • 市場の概要
  • 競合の評価

第3章 鎮痛剤市場の主な要因の分析

  • 鎮痛剤市場の促進要因
  • 鎮痛剤市場の抑制要因と課題
  • 鎮痛剤市場の機会

第4章 鎮痛剤市場のポーターのファイブフォース分析

第5章 鎮痛剤市場に対するCOVID-19の影響分析

第6章 鎮痛剤市場のレイアウト

  • 製品タイプ
    • オピオイド
    • 非オピオイド
  • 用途別
    • 筋骨格系
    • 手術、外傷
    • がん
    • その他
  • 薬剤タイプ別
    • 処方
    • OTC
  • 流通チャネル別
    • 病院、小売薬局
    • eコマース
  • 地域
    • 北米
    • 欧州
    • アジア太平洋
    • その他の地域

第7章 鎮痛剤市場の企業と製品のプロファイル

  • Bayer AG
  • Pfizer Inc.
  • AbbVie Inc.
  • Bristol-Myers Squibb Company
  • Endo Pharmaceuticals
  • Teva Pharmaceutical Industries Ltd.
  • Sanofi
  • Assertio Holdings, Inc.
  • Janssen Pharmaceuticals, Inc.
  • Novartis AG
  • GSK plc.
  • Perrigo Company plc.
  • Mallinckrodt
  • Purdue Pharma L.P.
  • Abbott
  • Reckitt Benckiser Group PLC.
  • Lilly
  • Fresenius Kabi USA
  • Hikma Pharmaceuticals PLC
  • Heron Therapeutics, Inc.

第8章 KOLの見解

第9章 プロジェクトアプローチ

第10章 DelveInsightについて

第11章 免責事項、お問い合わせ

図表

List of Tables

  • Table 1: Competitive Analysis
  • Table 2: COVID-19 Impact Analysis on Analgesics Market
  • Table 3: Analgesics Market in Global (2021-2030)
  • Table 4: Analgesics Market in Global by Product Type (2021-2030)
  • Table 5: Analgesics Market in Global by Applications (2021-2030)
  • Table 6: Analgesics Market in Global by Drug Type (2021-2030)
  • Table 7: Analgesics Market in Global by Distribution Channels (2021-2030)
  • Table 8: Analgesics Market in Global by Geography (2021-2030)
  • Table 9: Analgesics Market in North America (2021-2030)
  • Table 10: Analgesics Market in North America by Country (2021-2030)
  • Table 11: Analgesics Market in the US (2021-2030)
  • Table 12: Analgesics Market in Canada (2021-2030)
  • Table 13: Analgesics Market in Mexico (2021-2030)
  • Table 14: Analgesics Market in Europe (2021-2030)
  • Table 15: Analgesics Market in Europe by Country (2021-2030)
  • Table 16: Analgesics Market in France (2021-2030)
  • Table 17: Analgesics Market in Germany (2021-2030)
  • Table 18: Analgesics Market in the United Kingdom (2021-2030)
  • Table 19: Analgesics Market in Italy (2021-2030)
  • Table 20: Analgesics Market in Spain (2021-2030)
  • Table 21: Analgesics Market in the Rest of Europe (2021-2030)
  • Table 22: Analgesics Market in APAC (2021-2030)
  • Table 23: Analgesics Market in APAC by Country (2021-2030)
  • Table 24: Analgesics Market in China (2021-2030)
  • Table 25: Analgesics Market in Japan (2021-2030)
  • Table 26: Analgesics Market in India (2021-2030)
  • Table 27: Analgesics Market in Australia (2021-2030)
  • Table 28: Analgesics Market in South Korea (2021-2030)
  • Table 29: Analgesics Market in Rest of APAC (2021-2030)
  • Table 30: Analgesics Market in the Rest of the World (2021-2030)
  • Table 31: Analgesics Market in RoW by Region (2021-2030)
  • Table 32: Analgesics Market in the Middle East (2021-2030)
  • Table 33: Analgesics Market in Africa (2021-2030)
  • Table 34: Analgesics Market in South America (2021-2030)

List of Figures

  • Figure 1: Competitive Analysis
  • Figure 2: COVID-19 Impact Analysis on Analgesics Market
  • Figure 3: Analgesics Market in Global (2021-2030)
  • Figure 4: Analgesics Market in Global by Product Type (2021-2030)
  • Figure 5: Analgesics Market in Global by Application (2021-2030)
  • Figure 6: Analgesics Market in Global by Drug Type (2021-2030)
  • Figure 7: Analgesics Market in Global by Distribution Channel (2021-2030)
  • Figure 8: Analgesics Market in Global by Geography (2021-2030)
  • Figure 9: Analgesics Market in North America (2021-2030)
  • Figure 10: Analgesics Market in North America by Country (2021-2030)
  • Figure 11: Analgesics Market in the US (2021-2030)
  • Figure 12: Analgesics Market in Canada (2021-2030)
  • Figure 13: Analgesics Market in Mexico (2021-2030)
  • Figure 14: Analgesics Market in Europe (2021-2030)
  • Figure 15: Analgesics Market in Europe by Country (2021-2030)
  • Figure 16: Analgesics Market in France (2021-2030)
  • Figure 17: Analgesics Market in Germany (2021-2030)
  • Figure 18: Analgesics Market in the United Kingdom (2021-2030)
  • Figure 19: Analgesics Market in Italy (2021-2030)
  • Figure 20: Analgesics Market in Spain (2021-2030)
  • Figure 21: Analgesics Market in the Rest of Europe (2021-2030)
  • Figure 22: Analgesics Market in APAC (2021-2030)
  • Figure 23: Analgesics Market in APAC by Country (2021-2030)
  • Figure 24: Analgesics Market in China (2021-2030)
  • Figure 25: Analgesics Market in Japan (2021-2030)
  • Figure 26: Analgesics Market in India (2021-2030)
  • Figure 27: Analgesics Market in Australia (2021-2030)
  • Figure 28: Analgesics Market in South Korea (2021-2030)
  • Figure 29: Analgesics Market in Rest of APAC (2021-2030)
  • Figure 30: Analgesics Market in the Rest of the World (2021-2030)
  • Figure 31: Analgesics Market in RoW by Region (2021-2030)
  • Figure 32: Analgesics Market in the Middle East (2021-2030)
  • Figure 33: Analgesics Market in Africa (2021-2030)
  • Figure 34: Analgesics Market in South America (2021-2030)
  • Figure 35: Market Drivers
  • Figure 36: Market Barriers
  • Figure 37: Marker Opportunities
  • Figure 38: PORTER'S Five Force Analysis
目次
Product Code: DISR0085

Analgesics Market By Product Type (Opioid And Non-Opioid), By Application (Musculoskeletal, Surgical And Trauma, Cancer, And Others), By Drug Type (Prescription And Over-The-Counter (Otc)) By Distribution Channels (Hospital Pharmacy & Retail Pharmacy, And E-Commerce) by geography is estimated to register growth at a remarkable CAGR forecast during 2024-2030 owing to the increasing prevalence of orthopedic, cancer, and other chronic diseases and rising demand of analgesics for the treatment of mild to moderate pain

The global analgesics market was valued at USD 30,599 million in 2023, growing at a CAGR of 6.84% during the forecast period from 2024 to 2030 to reach USD 45,389 million by 2030. The analgesics market is slated to witness prosperity owing to the increasing prevalence of orthopedic, cancer, and other chronic diseases, the rising demand for analgesics for the treatment of mild to moderate pain, the growing burden of the geriatric population, and the growing focus on improving the safety, efficacy, and usability of analgesics for people are further expected to result in the appreciable revenue growth in the analgesics market during the forecast period (2024-2030).

Analgesics Market Dynamics:

According to the World Health Organization (WHO) 2022, globally nearly 2.26 million cases of breast cancer, 2.21 million cases of lung cancer, 1.93 million cases of colon and rectum cancer, 1.41 million cases of prostate cancer, and 1.09 million cases of stomach cancer were reported in 2020.

The rising prevalence of orthopedic diseases such as osteoarthritis, rheumatoid arthritis, and others is another important driver for the analgesics market. According to World Health Organization (WHO) 2022, musculoskeletal conditions are the leading contributor to disability and worldwide around 1.71 billion people are suffering from musculoskeletal diseases such as osteoporosis, osteoarthritis, rheumatoid arthritis, and others. According to WHO 2022, worldwide around 528 million people suffered from osteoarthritis in 2019. As per the same source, worldwide 18 million people had rheumatoid arthritis in 2019.

Osteoarthritis often referred to as degenerative or wear-and-tear arthritis affects the joints and eventually causes the smooth cartilage on the surface of the bones to wear away. Patients face significant pain, edema, and joint inflammation which limits their ability to move freely. Analgesics are thereby taken to treat the pain.

Additionally, the rising demand for analgesics for the treatment of mild to moderate pain such as in the case of toothache, headache, pain due to strenuous physical activity, period pain, and others is another factor accelerating the growth of the analgesics market.

However, growing concern over opioid abuse and stringent regulatory policies may act as a restraint in the market growth for analgesics.

The COVID-19 pandemic has slightly impacted the market for analgesics. During the initial stage of the pandemic, the sale of analgesics suffered a downfall owing to the imposition of strict lockdown rules, and disruption in manufacturing, and supply. Also, owing to the strict lockdown rules many elective surgeries and diagnosis sessions were postponed, impacting the demand for analgesics. However, there were analgesics such as acetaminophen (paracetamol), and others were taken by people suffering from COVID for relieving the symptoms such as fever and pain. Moreover, with the ease of lockdown restrictions, the upturn of resources and supply chain, the administration of vaccines to the public, and the increasing number of surgeries and diagnoses of chronic pain and inflammation-related diseases, the demand for analgesics is anticipated to grow and will do the same during the forecast period from 2022 - 2028.

Analgesics Market Segment Analysis:

Analgesics market by Product Type (Opioids and Non-Opioids), Drug Type (Prescription and OTC), Distribution Channels (Hospital Pharmacy & Retail Pharmacy, and E-Commerce), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)

Based on the product type segment of the analgesics market, the non-opioids category is projected to register a significant growth in revenue in the overall analgesics market during the forecast period (2024-2030). Non-opioid analgesics are suitable and effective for a wide variety of pain and inflammatory conditions including musculoskeletal pain due to rheumatic disorders. They seem to have fewer side effects associated with them than opioid analgesics.

The commonly used analgesics are acetaminophen (paracetamol), antidepressants such as duloxetine and amitriptyline, aspirin and other non-steroidal anti-inflammatory agents (NSAIDS), and topical agents such as lidocaine and capsaicin among others.

Acetaminophen is indicated for mild to moderate pain such as in case of headache, period pain, backaches, and others. It is regarded as the first line of therapy for pain and fever, particularly in the case of viral infections.

Non-steroidal anti-inflammatory drugs (NSAIDs) can reduce pain, have antipyretic properties, prevent blood clots, and can reduce inflammation by blocking enzymes such as prostaglandins that are responsible for causing pain and inflammation in the body.

The increasing number of research studies related to the evaluation of the role of non-opioid analgesics is further going to enhance the demand for non-opioid analgesics. For instance, in November 2022, Northwestern University in collaboration with the National Institutes of Health (NIH) started a clinical study that aims to determine whether the treatment with Carbidopa/Levodopa and Naproxen in females with acute pain after a bunionectomy or toe fusion (24hrs, 48hrs and 5 days) will reduce pain when compared with females receiving Placebo and Naproxen.

Therefore, owing to the above-mentioned factors, the non-opioids category is expected to generate considerable revenue thereby pushing the overall growth of the global analgesics market during the forecast period.

North America is expected to dominate the overall Analgesics Market:

Among all the regions, North America is expected to lead in revenue generation in the global analgesics market. This can be due to factors including the prevalence of chronic and infectious diseases such as orthopedic, cardiovascular, tuberculosis, and cancer among others, the increasing old age population, and the presence of key companies involved in the development of analgesics, and others.

The rising prevalence of arthritis in the US is the major factor responsible for the growth of the analgesics market in the region. As per the Centers for Disease Control and Prevention (CDC) 2022, it has been estimated that there will be around 78.4 million people suffering from doctor-diagnosed arthritis by 2040, and out of that two-thirds will be the women population.

As per the same source, an estimated 34.6 million adults will face arthritis-attributable activity limitations in the US by 2040. As per Arthritis Foundation 2022, around 1.5 million people have rheumatoid arthritis in the United States.

Moreover, as per the figures mentioned by the American Cancer Society 2022, it was estimated that 1.9 million new cancer cases have been diagnosed in the United States in 2022. Also, according to the data provided by the Centers for Disease Control and Prevention (CDC) in 2022, around 1,752,735 new cases of cancer were reported in the US in 2019.

Along with the presence of a large patient pool in the country, the increasing focus of manufacturers on launching new products in the market is expected to bolster the growth of the analgesics market in the United States during the forecast period.

For example, in October 2022, Esteve Pharmaceuticals received the US Food and Drug Administration (FDA) clearance for SEGLENTIS® (celecoxib and tramadol hydrochloride) for the management of acute pain in adults that is severe enough to require an opioid analgesic and for which alternative treatments are inadequate.

Therefore, the above-mentioned factors are expected to bolster the growth of the analgesics market in the United States during the forecast period.

Analgesics Market Key Players:

Some of the key market players operating in the Analgesics market include Novartis AG, Pfizer Inc., Bayer AG, AbbVie Inc., Bristol-Myers Squibb Company, Endo Pharmaceuticals, Teva Pharmaceutical Industries Ltd., Sanofi, Assertio Holdings, Inc., Janssen Pharmaceuticals, Inc., GSK plc., Perrigo Company plc., Mallinckrodt, Purdue Pharma L.P., Abbott, Reckitt Benckiser Group PLC., Fresenius Kabi USA, Lilly, Hikma Pharmaceuticals PLC, Heron Therapeutics, Inc., and others.

Recent Developmental Activities in the Analgesics Market:

In November 2022, Pacira Biosciences announced the acquisition of flexion therapeutics and strengthened its leadership position in non-opioid pain management.

In August 2020, Trevena, Inc., received US FDA approval for an intravenous opioid analgesic OLINVYK.

Key Takeaways from the Analgesics Market Report Study

Market size analysis for current analgesics market size (2023), and market forecast for 5 years (2024-2030)

The effect of the COVID-19 pandemic on this market is significant. to capture and analyze suitable indicators, our experts are closely watching the analgesics market.

Top key product developments, mergers, acquisitions, partnerships, and joint ventures happened over the last 3 years

Key companies dominating the global analgesics market.

Various opportunities available for the other competitor in the analgesics market space.

What are the top-performing segments in 2023? How these segments will perform in 2030?

Which are the top-performing regions and countries in the current analgesics market scenario?

Which are the regions and countries where companies should have concentrated on opportunities for analgesics market growth in the coming future?

Target Audience who can be benefited from this Analgesics Market Report Study

Analgesics products providers

Research organizations and consulting companies

Analgesics -related organizations, associations, forums, and other alliances

Government and corporate offices

Start-up companies, venture capitalists, and private equity firms

Distributors and Traders dealing in analgesics

Various distribution channels want to know more about the analgesics market and the latest product innovations in the analgesics market.

Frequently Asked Questions for the Analgesics Market:

1. What are Analgesics?

Analgesics, commonly known as painkillers are medications intended for reducing and relieving pain caused because of different conditions including headache, injury, surgery, arthritis, or any other disease.

2. What is the market for global Analgesics?

The global analgesics market was valued at USD 30,599 million in 2023, growing at a CAGR of 6.84% during the forecast period from 2024 to 2030 to reach USD 45,389 million by 2030.

3. What are the drivers for the global analgesics market?

The analgesics market is slated to witness prosperity owing to factors such as the increasing prevalence of orthopedic, cancer, and other chronic diseases, rising demand for analgesics for the treatment of mild to moderate pain, the growing burden of the geriatric population, and the growing focus on improving the safety, efficacy, and usability of analgesics for people is further expected to result in the appreciable revenue growth in the analgesics market during the forecast period (2024-2030).

4. Who are the key players operating in the global analgesics market?

Some of the key market players operating in the analgesics market include Novartis AG, Pfizer Inc., Bayer AG, AbbVie Inc., Bristol-Myers Squibb Company, Endo Pharmaceuticals, Teva Pharmaceutical Industries Ltd., Sanofi, Assertio Holdings, Inc., Janssen Pharmaceuticals, Inc., GSK plc., Perrigo Company plc., Mallinckrodt, Purdue Pharma L.P., Abbott, Reckitt Benckiser Group PLC., Fresenius Kabi USA, Lilly, Hikma Pharmaceuticals PLC, Heron Therapeutics, Inc., and others.

5. Which region has the highest share in the analgesics market?

North America is expected to dominate the overall analgesics market during the forecast period, 2024 to 2030. This can be ascribed to the increasing prevalence of orthopedic, cancer, and other diseases responsible for causing chronic and acute pain, the increasing geriatric population, a highly potent market in terms of product development and launches, and the local presence of key market players among other factors in the region.

Table of Contents

1.Analgesics Market Report Introduction

2. Analgesics Market Executive Summary

  • 2.1. Scope of the Study
  • 2.2. Market at Glance
  • 2.3. Competitive Assessment

3. Analgesics Market Key Factors Analysis

  • 3.1. Analgesics Market Drivers
    • 3.1.1. The increasing prevalence of orthopedic, cancer, and other chronic diseases
    • 3.1.2. Rising demand for analgesics for the treatment of mild to moderate pain
    • 3.1.3. The growing burden of the geriatric population
  • 3.2. Analgesics Market Restraints and Challenges
    • 3.2.1. Growing concern over opioids abuse and opioid tolerance
    • 3.2.2. Increasing adoption of biologics for pain management
  • 3.3. Analgesics Market Opportunities
    • 3.3.1. Surging strategic activities such as acquisitions, partnerships, r&d, and others
    • 3.3.2. Government initiatives to spur pharmaceutical sector growth

4. Analgesics Market Porter's Five Forces Analysis

  • 4.1. Bargaining Power of Suppliers
  • 4.2. Bargaining Power of Consumers
  • 4.3. Threat of New Entrants
  • 4.4. Threat of Substitutes
  • 4.5. Competitive Rivalry

5. COVID-19 Impact Analysis on Analgesics Market

6. Analgesics Market Layout

  • 6.1. By Product Type
    • 6.1.1. Opioids
    • 6.1.2. Non-Opioids
  • 6.2. By Application
    • 6.2.1. Musculoskeletal
    • 6.2.2. Surgery and Trauma
    • 6.2.3. Cancer
    • 6.2.4. Others
  • 6.3. By Drug Type
    • 6.3.1. Prescription
    • 6.3.2. Over The Counter (OTC)
  • 6.4. By Distribution Channels
    • 6.4.1. Hospital and Retail Pharmacy
    • 6.4.2. E-commerce
  • 6.5. By Geography
    • 6.5.1. North America
      • 6.5.1.1. United States Analgesics Market in USD million (2021-2030)
      • 6.5.1.2. Canada Analgesics Market in USD million (2021-2030)
      • 6.5.1.3. Mexico Analgesics Market in USD million (2021-2030)
    • 6.5.2. Europe
      • 6.5.2.1. France Analgesics Market in USD million (2021-2030)
      • 6.5.2.2. Germany Analgesics Market in USD million (2021-2030)
      • 6.5.2.3. United Kingdom Analgesics Market in USD million (2021-2030)
      • 6.5.2.4. Italy Analgesics Market in USD million (2021-2030)
      • 6.5.2.5. Spain Analgesics Market in USD million (2021-2030)
      • 6.5.2.6. Rest of Europe Analgesics Market in USD million (2021-2030)
    • 6.5.3. Asia-Pacific
      • 6.5.3.1. China Analgesics Market in USD million (2021-2030)
      • 6.5.3.2. Japan Analgesics Market in USD million (2021-2030)
      • 6.5.3.3. India Analgesics Market in USD million (2021-2030)
      • 6.5.3.4. Australia Analgesics Market in USD million (2021-2030)
      • 6.5.3.5. South Korea Analgesics Market in USD million (2021-2030)
      • 6.5.3.6. Rest of the Asia Pacific Analgesics Market in USD million (2021-2030)
    • 6.5.4. Rest of the World (RoW)
      • 6.5.4.1. Middle East Analgesics Market in USD million (2021-2030)
      • 6.5.4.2. Africa Analgesics Market in USD million (2021-2030)
      • 6.5.4.3. South America Analgesics Market in USD million (2021-2030)

7. Analgesics Market Company and Product Profiles

  • 7.1. Bayer AG
    • 7.1.1. Company Overview
    • 7.1.2. Company Snapshot
    • 7.1.3. Financial Overview
    • 7.1.4. Product Listing
    • 7.1.5. Entropy
  • 7.2. Pfizer Inc.
    • 7.2.1. Company Overview
    • 7.2.2. Company Snapshot
    • 7.2.3. Financial Overview
    • 7.2.4. Product Listing
    • 7.2.5. Entropy
  • 7.3. AbbVie Inc.
    • 7.3.1. Company Overview
    • 7.3.2. Company Snapshot
    • 7.3.3. Financial Overview
    • 7.3.4. Product Listing
    • 7.3.5. Entropy
  • 7.4. Bristol-Myers Squibb Company
    • 7.4.1. Company Overview
    • 7.4.2. Company Snapshot
    • 7.4.3. Financial Overview
    • 7.4.4. Product Listing
    • 7.4.5. Entropy
  • 7.5. Endo Pharmaceuticals
    • 7.5.1. Company Overview
    • 7.5.2. Company Snapshot
    • 7.5.3. Financial Overview
    • 7.5.4. Product Listing
    • 7.5.5. Entropy
  • 7.6. Teva Pharmaceutical Industries Ltd.
    • 7.6.1. Company Overview
    • 7.6.2. Company Snapshot
    • 7.6.3. Financial Overview
    • 7.6.4. Product Listing
    • 7.6.5. Entropy
  • 7.7. Sanofi
    • 7.7.1. Company Overview
    • 7.7.2. Company Snapshot
    • 7.7.3. Financial Overview
    • 7.7.4. Product Listing
    • 7.7.5. Entropy
  • 7.8. Assertio Holdings, Inc.
    • 7.8.1. Company Overview
    • 7.8.2. Company Snapshot
    • 7.8.3. Financial Overview
    • 7.8.4. Product Listing
    • 7.8.5. Entropy
  • 7.9. Janssen Pharmaceuticals, Inc.
    • 7.9.1. Company Overview
    • 7.9.2. Company Snapshot
    • 7.9.3. Financial Overview
    • 7.9.4. Product Listing
    • 7.9.5. Entropy
  • 7.10. Novartis AG
    • 7.10.1. Company Overview
    • 7.10.2. Company Snapshot
    • 7.10.3. Financial Overview
    • 7.10.4. Product Listing
    • 7.10.5. Entropy
  • 8.11. GSK plc.
    • 8.11.1. Company Overview
    • 8.11.2. Company Snapshot
    • 8.11.3. Financial Overview
    • 8.11.4. Product Listing
    • 8.11.5. Entropy
  • 8.12. Perrigo Company plc.
    • 8.12.1. Company Overview
    • 8.12.2. Company Snapshot
    • 8.12.3. Financial Overview
    • 8.12.4. Product Listing
    • 8.12.5. Entropy
  • 8.13. Mallinckrodt
    • 8.13.1. Company Overview
    • 8.13.2. Company Snapshot
    • 8.13.3. Financial Overview
    • 8.13.4. Product Listing
    • 8.13.5. Entropy
  • 8.14. Purdue Pharma L.P.
    • 8.14.1. Company Overview
    • 8.14.2. Company Snapshot
    • 8.14.3. Financial Overview
    • 8.14.4. Product Listing
    • 8.14.5. Entropy
  • 8.15. Abbott
    • 8.15.1. Company Overview
    • 8.15.2. Company Snapshot
    • 8.15.3. Financial Overview
    • 8.15.4. Product Listing
    • 8.15.5. Entropy
  • 8.16. Reckitt Benckiser Group PLC.
    • 8.16.1. Company Overview
    • 8.16.2. Company Snapshot
    • 8.16.3. Financial Overview
    • 8.16.4. Product Listing
    • 8.16.5. Entropy
  • 8.17. Lilly
    • 8.17.1. Company Overview
    • 8.17.2. Company Snapshot
    • 8.17.3. Financial Overview
    • 8.17.4. Product Listing
    • 8.17.5. Entropy
  • 8.18. Fresenius Kabi USA
    • 8.18.1. Company Overview
    • 8.18.2. Company Snapshot
    • 8.18.3. Financial Overview
    • 8.18.4. Product Listing
    • 8.18.5. Entropy
  • 8.19. Hikma Pharmaceuticals PLC
    • 8.19.1. Company Overview
    • 8.19.2. Company Snapshot
    • 8.19.3. Financial Overview
    • 8.19.4. Product Listing
    • 8.19.5. Entropy
  • 8.20. Heron Therapeutics, Inc.
    • 8.20.1. Company Overview
    • 8.20.2. Company Snapshot
    • 8.20.3. Financial Overview
    • 8.20.4. Product Listing
    • 8.20.5. Entropy

8. KOL Views

9. Project Approach

10. About DelveInsight

11. Disclaimer & Contact Us